Skip to contentP
Palvella Therapeutics, Inc.
P
PVLAPalvella Therapeutics, Inc. Q4 2017 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$18.15M$18.15Mderived+565.8% vs Q4 2016 Net Income$7.49M$7.49MderivedN/M vs Q4 2016 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Palvella Therapeutics, Inc. · CIK 1583648 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived$6,487,000N/M Operating Cash Flowderived-$4,694,000N/M Free Cash Flowderived-$5,513,000N/M Margins · derivedOperating margin35.7%+270.7 pt vs Q4 2016
Net margin41.3%+281.8 pt vs Q4 2016
ended Dec 31, 2017 · filed Mar 15, 2018 · 74 d after period end